메뉴 건너뛰기




Volumn 18, Issue 8, 2012, Pages 2290-2300

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ANGIOPOIETIN 2; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; PLACEBO; RAS PROTEIN; SCATTER FACTOR; SOMATOMEDIN B; SORAFENIB; STEM CELL FACTOR; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

EID: 84859880607     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2175     Document Type: Article
Times cited : (462)

References (57)
  • 2
    • 63049133092 scopus 로고    scopus 로고
    • Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
    • Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
    • (2009) J Clin Oncol , vol.27 , pp. 1485-1491
    • Altekruse, S.F.1    McGlynn, K.A.2    Reichman, M.E.3
  • 3
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • SHARP Investigators Study Group
    • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3    Hilgard, P.4    Gane, E.5    Blanc, J.F.6
  • 4
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo- Controlled trial
    • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo- controlled trial. Lancet Oncol 2009;10:25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3    Tsao, C.J.4    Qin, S.5    Kim, J.S.6
  • 5
    • 44449085884 scopus 로고    scopus 로고
    • Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma
    • Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 698-711
    • Llovet, J.M.1    Di Bisceglie, A.M.2    Bruix, J.3    Kramer, B.S.4    Lencioni, R.5    Zhu, A.X.6
  • 6
    • 79952231921 scopus 로고    scopus 로고
    • American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update
    • Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
    • (2011) Hepatology , vol.53 , pp. 1020-1022
    • Bruix, J.1    Sherman, M.2
  • 7
    • 41649102043 scopus 로고    scopus 로고
    • The cancer biomarker problem
    • DOI 10.1038/nature06913, PII NATURE06913
    • Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52. (Pubitemid 351483368)
    • (2008) Nature , vol.452 , Issue.7187 , pp. 548-552
    • Sawyers, C.L.1
  • 8
    • 0033071014 scopus 로고    scopus 로고
    • Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein
    • Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999;14:256-71.
    • (1999) Int J Oncol , vol.14 , pp. 256-271
    • Okuda, K.1    Tanaka, M.2    Kanazawa, N.3    Nagashima, J.4    Satomura, S.5    Kinoshita, H.6
  • 9
    • 73349142702 scopus 로고    scopus 로고
    • Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival
    • Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-42.
    • (2009) J Clin Oncol , vol.27 , pp. 5734-5742
    • Riaz, A.1    Ryu, R.K.2    Kulik, L.M.3    Mulcahy, M.F.4    Lewandowski, R.J.5    Minocha, J.6
  • 10
    • 78649296731 scopus 로고    scopus 로고
    • Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma
    • Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010;55:3576-83.
    • (2010) Dig Dis Sci , vol.55 , pp. 3576-3583
    • Tamura, Y.1    Igarashi, M.2    Kawai, H.3    Suda, T.4    Satomura, S.5    Aoyagi, Y.6
  • 12
    • 75549088882 scopus 로고    scopus 로고
    • EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
    • Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280-1.
    • (2010) J Hepatol , vol.52 , pp. 280-281
    • Terris, B.1    Cavard, C.2    Perret, C.3
  • 14
    • 60449087921 scopus 로고    scopus 로고
    • EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features
    • Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-24.
    • (2009) Gastroenterology , vol.136 , pp. 1012-1024
    • Yamashita, T.1    Ji, J.2    Budhu, A.3    Forgues, M.4    Yang, W.5    Wang, H.Y.6
  • 15
    • 70349871321 scopus 로고    scopus 로고
    • MicroRNA expression, survival, and response to interferon in liver cancer
    • Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
    • (2009) N Engl J Med , vol.361 , pp. 1437-1447
    • Ji, J.1    Shi, J.2    Budhu, A.3    Yu, Z.4    Forgues, M.5    Roessler, S.6
  • 18
    • 54449083925 scopus 로고    scopus 로고
    • Molecular targeted therapies in hepatocellular carcinoma
    • Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
    • (2008) Hepatology , vol.48 , pp. 1312-1327
    • Llovet, J.M.1    Bruix, J.2
  • 19
    • 84859212951 scopus 로고    scopus 로고
    • Hepatocellular carcinoma
    • in press. DOI:10.1016/S0140-6736(11)61347-0
    • Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, in press. DOI:10.1016/S0140-6736(11)61347-0.
    • (2012) Lancet
    • Forner, A.1    Llovet, J.M.2    Bruix, J.3
  • 21
    • 55749088393 scopus 로고    scopus 로고
    • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    • Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
    • (2008) Mol Cancer Ther , vol.7 , pp. 3129-3140
    • Wilhelm, S.M.1    Adnane, L.2    Newell, P.3    Villanueva, A.4    Llovet, J.M.5    Lynch, M.6
  • 23
    • 0031690845 scopus 로고    scopus 로고
    • Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma
    • DOI 10.1016/S0046-8177(98)90205-2
    • Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-91. (Pubitemid 28422048)
    • (1998) Human Pathology , vol.29 , Issue.9 , pp. 986-991
    • Torimura, T.1    Sata, M.2    Ueno, T.3    Kin, M.4    Tsuji, R.5    Suzaku, K.6    Hashimoto, O.7    Sugawara, H.8    Tanikawa, K.9
  • 24
    • 59149098933 scopus 로고    scopus 로고
    • Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy
    • Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, et al. Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2009;13:325-33.
    • (2009) J Gastrointest Surg , vol.13 , pp. 325-333
    • Mizuguchi, T.1    Nagayama, M.2    Meguro, M.3    Shibata, T.4    Kaji, S.5    Nobuoka, T.6
  • 28
    • 84984586846 scopus 로고    scopus 로고
    • Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
    • Omata M, Lesmana LA, Tateishi R, Chen PJ, Lim SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
    • (2010) Hepatol Int , vol.4 , pp. 439-474
    • Omata, M.1    Lesmana, L.A.2    Tateishi, R.3    Chen, P.J.4    Lim, S.M.5    Yoshida, H.6
  • 29
    • 71249126197 scopus 로고    scopus 로고
    • Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009
    • Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-8.
    • (2009) Lancet Oncol , vol.10 , pp. 1111-1118
    • Poon, D.1    Anderson, B.O.2    Chen, L.T.3    Tanaka, K.4    Lau, W.Y.5    Van Cutsem, E.6
  • 31
    • 0038118504 scopus 로고    scopus 로고
    • Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
    • DOI 10.1097/01.MP.0000071841.17900.69
    • Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16:552-7. (Pubitemid 36718436)
    • (2003) Modern Pathology , vol.16 , Issue.6 , pp. 552-557
    • Moon, W.S.1    Rhyu, K.H.2    Kang, M.J.3    Lee, D.G.4    Yu, H.C.5    Yeum, J.H.6    Koh, G.Y.7    Tarnawski, A.S.8
  • 32
    • 65549105393 scopus 로고    scopus 로고
    • Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis
    • Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92.
    • (2009) Br J Cancer , vol.100 , pp. 1385-1392
    • Schoenleber, S.J.1    Kurtz, D.M.2    Talwalkar, J.A.3    Roberts, L.R.4    Gores, G.J.5
  • 33
    • 70350507211 scopus 로고    scopus 로고
    • Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature
    • Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-906.
    • (2009) Cancer , vol.115 , pp. 4895-4906
    • Kaseb, A.O.1    Hanbali, A.2    Cotant, M.3    Hassan, M.M.4    Wollner, I.5    Philip, P.A.6
  • 34
    • 80053974116 scopus 로고    scopus 로고
    • Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    • Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9.
    • (2011) J Clin Oncol , vol.29 , pp. 3892-3899
    • Kaseb, A.O.1    Morris, J.S.2    Hassan, M.M.3    Siddiqui, A.M.4    Lin, E.5    Xiao, L.6
  • 35
    • 77957570088 scopus 로고    scopus 로고
    • Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial
    • Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010;16:4853-63.
    • (2010) Clin Cancer Res , vol.16 , pp. 4853-4863
    • Pena, C.1    Lathia, C.2    Shan, M.3    Escudier, B.4    Bukowski, R.M.5
  • 36
    • 70149087258 scopus 로고    scopus 로고
    • Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    • Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24.
    • (2009) Anticancer Drugs , vol.20 , pp. 616-624
    • Bianchi, G.1    Loibl, S.2    Zamagni, C.3    Salvagni, S.4    Raab, G.5    Siena, S.6
  • 37
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • Zhu AX, Dahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35.
    • (2009) J Clin Oncol , vol.27 , pp. 3027-3035
    • Zhu, A.X.1    Dahani, D.V.2    Duda, D.G.3    Di Tomaso, E.4    Ancukiewicz, M.5    Catalano, O.A.6
  • 38
    • 79960590467 scopus 로고    scopus 로고
    • Mechanism-related circulating proteins as biomarkers for clinical outcomes in patients with unresectable hepatocellular carcinoma receiving sunitinib
    • Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, et al. Mechanism-related circulating proteins as biomarkers for clinical outcomes in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120.
    • (2011) J Transl Med , vol.9 , pp. 120
    • Harmon, C.S.1    DePrimo, S.E.2    Raymond, E.3    Cheng, A.L.4    Boucher, E.5    Douillard, J.Y.6
  • 39
    • 34547779489 scopus 로고    scopus 로고
    • Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins
    • DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
    • (2007) J Transl Med , vol.5 , pp. 32
    • DePrimo, S.E.1    Bello, C.L.2    Smeraglia, J.3    Baum, C.M.4    Spinella, D.5    Rini, B.I.6
  • 42
    • 62349110279 scopus 로고    scopus 로고
    • A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic markers
    • Baar J, Silverman S, Lyons J, Fu P, Abdul-Karim F, Ziats N, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic markers. Clin Cancer Res 2009;15:3583-90.
    • (2009) Clin Cancer Res , vol.15 , pp. 3583-3590
    • Baar, J.1    Silverman, S.2    Lyons, J.3    Fu, P.4    Abdul-Karim, F.5    Ziats, N.6
  • 43
    • 46449091500 scopus 로고    scopus 로고
    • Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocelllular carcinoma
    • Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocelllular carcinoma. J Clin Oncol 2008;36:2992-8.
    • (2008) J Clin Oncol , vol.36 , pp. 2992-2998
    • Siegel, A.B.1    Cohen, E.I.2    Ocean, A.3    Lehrer, D.4    Goldenberg, A.5    Knox, J.J.6
  • 44
    • 79954451405 scopus 로고    scopus 로고
    • Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    • Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9.
    • (2011) Br J Cancer , vol.104 , pp. 1262-1269
    • Loupakis, F.1    Cremolini, C.2    Fioravanti, A.3    Orlandi, P.4    Salvatore, L.5    Masi, G.6
  • 46
  • 50
    • 84857102544 scopus 로고    scopus 로고
    • South San Francisco, CA: Genentech USA, Inc. [updated 2010 Oct; cited 2011 Nov 28]. Available from
    • Herceptin (trastuzumab) prescribing information. South San Francisco, CA: Genentech USA, Inc. [updated 2010 Oct; cited 2011 Nov 28]. Available from: http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf.
    • Herceptin (Trastuzumab) Prescribing Information
  • 52
    • 74049152132 scopus 로고    scopus 로고
    • Thousand Oaks, CA: Amgen Inc. [updated 2011 Jun; cited 2011 Nov 28]. Available from
    • Vectibix (panitumumab) prescribing information. Thousand Oaks, CA: Amgen Inc. [updated 2011 Jun; cited 2011 Nov 28]. Available from: http://pi.amgen.com/ united-states/vectibix/vectibix-pi.pdf.
    • Vectibix (Panitumumab) Prescribing Information
  • 53
    • 84859815479 scopus 로고    scopus 로고
    • South San Francisco, CA: Genentech USA, Inc. [updated 2011 Aug; cited 2011 Nov 28]. Available from
    • Zelboraf (vemurafenib) prescribing information. South San Francisco, CA: Genentech USA, Inc. [updated 2011 Aug; cited 2011 Nov 28]. Available from: http://www.gene.com/gene/products/information/zelboraf/pdf/pi.pdf.
    • Zelboraf (Vemurafenib) Prescribing Information
  • 54
    • 84859837695 scopus 로고    scopus 로고
    • Philadelphia, PA: Pfizer Inc. [updated 2011 Oct; cited 2011 Nov 28]. Available from
    • Xalkori (crizotinib) prescribing information. Philadelphia, PA: Pfizer Inc. [updated 2011 Oct; cited 2011 Nov 28]. Available from: http://labeling. pfizer.com/showlabeling.aspx?id=676.
    • Xalkori (Crizotinib) Prescribing Information
  • 55
    • 33745220780 scopus 로고    scopus 로고
    • Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
    • Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95.
    • (2006) J Clin Invest , vol.116 , pp. 1582-1595
    • Kaposi-Novak, P.1    Lee, J.S.2    Gomez-Quiroz, L.3    Coulouarn, C.4    Factor, V.M.5    Thorgeirsson, S.S.6
  • 56
    • 33846212284 scopus 로고    scopus 로고
    • Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    • DOI 10.1158/0008-5472.CAN-06-1377
    • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8. (Pubitemid 46094197)
    • (2006) Cancer Research , vol.66 , Issue.24 , pp. 11851-11858
    • Liu, L.1    Cao, Y.2    Chen, C.3    Zhang, X.4    McNabola, A.5    Wilkie, D.6    Wilhelm, S.7    Lynch, M.8    Carter, C.9
  • 57
    • 77956654766 scopus 로고    scopus 로고
    • Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma
    • Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010;16:4616-24.
    • (2010) Clin Cancer Res , vol.16 , pp. 4616-4624
    • Kasahara, K.1    Arao, T.2    Sakai, K.3    Matsumoto, K.4    Sakai, A.5    Kimura, H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.